Letermovir Approved for Cytomegalovirus Prophylaxis in Kidney Transplant Recipients
Letermovir appears to be better tolerated than the current standard of care, valganciclovir, a prodrug of ganciclovir, which frequently causes myelosuppression.
Letermovir appears to be better tolerated than the current standard of care, valganciclovir, a prodrug of ganciclovir, which frequently causes myelosuppression.
Kidney transplant recipients with bacteremia may be more likely to require outpatient parenteral antibiotics if the infection is caused by bacteria that produce extended-spectrum beta-lactamases.
Short-term outcomes appear acceptable for transplanting COVID-19-positive donor kidneys.
The risks for sudden cardiac death from certain QT-prolonging antibiotics increase with steeper serum to dialysate potassium gradients.
Odds of infection, venous thromboembolism, renal complications increased for patients with overweight, obesity
Essential practices include administration of prophylaxis, which should be discontinued at time of surgical closure
Adverse events rates have been rising over time among patients receiving dialysis, investigators reported.
Reduced CD4 count linked to higher risk for opportunistic infection and invasive cancer, lower risk for autoimmunity
Heavy mycobacterial growth identified in ice and water machine on the unit where the 4 cardiac surgery patients were admitted
Despite declining rates of vascular access complications in the United States, Black patients remain at higher risk for them compared with White patients.